Summary The serine protease urokinase plasminogen activator (uPA) is causally involved in cancer invasion and metastasis. Activity of this protease in vivo is controlled principally by two inhibitors, one of which is plasminogen activator inhibitor type 2 (PAI-2). In this study, we show that PAI-2 levels were significantly higher in primary breast carcinomas (n = 152) than benign breast tumours (n = 18). In the primary cancers, PAI-2 levels correlated weakly but significantly with those of uPA and PAI-1, but not with tissue type plasminogen activator (tPA) or uPA receptor (uPAR) levels. Using Northern blotting, mRNA for PAI-2 was&found in 28.6% of 49 primary breast cancers. In contrast to findings at the protein level, PAI-2 mRNA levels failed to correlate with those for uPA or PAI-1. After immunocytochemistry with primary cancers, PAI-2 was detected predominantly in the malignant cells of primary carcinomas but was also present in stromal cells. Using the median value as a cut-off point, PAI-2 showed no significant relationship with either disease-free interval or overall survival. However, using an optimum cut-off value, patients with low levels of PAI-2 had a worse outcome than those with a high level. We conclude that, unlike PAI-1, high levels of PAI-2 may be a favourable prognostic marker in breast cancer.
Urokinase plasminogen activator (uPA) is a serine protease that is causally involved in cancer invasion and metastasis (for review, see Duffy, 1993) . Consistent with its role in cancer spread, uPA has been shown to be a prognostic marker in many different types of human cancer (for review, see Duffy, 1996) . As with most proteases, activity of uPA is regulated in vivo by inhibitors. The two best-characterized endogenous inhibitors of uPA are plasminogen activator inhibitor type 1 (PAI-1) and PAI-2. Both PAI-I and PAI-2 belong to the serpin family of protease inhibitors (Astedt et al, 1987; Andreasen et al, 1990) . PAI-I is a 52-kDa protein, whereas PAI-2 exists in two forms: a 60-kDa glycosylated secreted form and a 47-kDa non-glycosylated form. Both PAI-I and PAI-2 have been shown to inhibit extracellular matrix (ECM) degradation in vitro (Baker et al, 1990; Cajot et al, 1990) . Furthermore, administration of a recombinant PAI-2 to mice decreases tumour growth (Astedt et al, 1995) , whereas overexpression of either PAI-I or PAI-2 results in inhibition of metastasis (Mueller et al, 1995; Soff et al, 1995) . These effects of PAI-I and PAI-2 are probably mediated through inhibition of uPA activity.
Although PAI-I has been extensively studied in human cancers, especially breast cancer (Gr0ndahl-Hansen et al, 1993; Janicke et al, 1993; Reilly et al, 1992; Bianchi et al, 1995) , less information is available on PAI-2 levels in human malignancies (Bouchet et al, 1994; Foekens et al, 1995) . The aim of this investigation was, therefore, to study PAI-2 in different types of breast tumours and to relate its levels to other components of the plasminogen activator system, to pathological characteristics of the tumours and, finally, to patient outcome.
enzyme-linked immunosorbent assay uPA, uPA receptor (uPAR), tPA, PAI-I and PAI-2 were all assayed as described previously (Duggan et al, 1995) . Briefly, tumours were homogenized in 50 mM Tris buffer (pH 7.4) containing 1 mM monothiolglycerol. The homogenate was centrifuged at 2000 g for 10 min and the supematant extracted with 1% Triton X-100. Centrifugation was then carried out at 10000 g for 20 min at 4°C. uPA, uPAR, PAI-1, PAI-2 and tPA were assayed on the supernatant using enzyme-linked immunosorbent assay (ELISA) (kits obtained from American Diagnostica, Greenwich, CT, USA). The PAI-1 assay detects both latent and active forms of PAI-I as well as PAI-I complexed to uPA. It does not react with PAI-2. The PAI-2 ELISA detects both low and high molecular weight forms of this inhibitor as well as uPA-PAI-2 complexes. This assay is insensitive to PAI-1. The specificity of the uPA and uPAR assays has been described previously (Duggan et al, 1995) . The tPA assay measures free tPA and tPA complexed to both PAI-I and c2-antiplasmin. The main characteristics of the primary cancers used for the ELISAs are summarized in Table 1 . Of the 152 patients with primary breast cancer, follow-up information was available on 148. Median patient follow-up was 5.50 years. Adjuvant therapies administered are also listed in Table 1 . Levels of total protein were determined using the Bio-Rad Protein Assay (Bio-Rad).
Assay of oestrogen receptor (ER) in breast tumours
Breast tumour cytosols were assayed for oestrogen receptors (ER) using ELISA as described by Duffy et al (1986) . The cut-off point used was 200 fmol g-1 tissue.
Detection of mRNA for uPA, uPAR, tPA, PAI-1 and PAI-2 by Northern blotting Total RNA was extracted using guanidinium thiocyanate as described by Chomczynski et al (1987) . Integrity was checked on a 1% agarose gel, whereas concentration and purity were determined by measuring the OD at 260 nm and 280 nm respectively. Before electrophoresis, the RNA was denatured at 700C using 50% (v/v) formamide and 16.6% (v/v) formaldehyde. Electrophoresis was carried out on a 6-mm-thick 1% agarose-formaldehyde gel for 2-3 h at 100 V. After separation under denaturing conditions, RNA was transferred to Hybond-N membranes and the mRNA species of interest located by hybridization with 32P-labelled cDNA probes. mRNA band position was verified by measuring the distance migrated with respect to a 0.24-to 9.5-kb RNA marker.
Preparation of oligonucleotide probes Oligonucleotide probes were generated by polymerase chain reaction (PCR) fronm a human placental cDNA library in kgtl 1 (Clontech). The primer sequences used were as follows: Probe specificity was confirmed by carrying out BLAST searches against the EMBL database. Sequence homologies for each of the probes corresponded to their target gene sequence. In addition, both the hybridization and washing conditions were highly stringent (2 x SSC, and 2 x SSC/0. 1% SDS at 65°C respectively).
Semiquantitation of mRNAs
The radiolabelled blots were exposed to phosphor screens for 48 h and analysed using a Molecular Dynamics Phosphor Imager 425, and ImageQuant software. The band intensity of uPA, PAI-1, PAI-2, uPAR and tPA were expressed relative to that of GAPDH, which was used as the internal control. 
Statistical analysis
The strength of associations between the various parameters measured were tested using non-parametric tests. The Kruskall-Wallis and Mann-Whitney tests were used for categorical variables, and the Spearman rank correlation was used for continuous variables. Survival analysis was carried out using the log-rank test in association with Kaplan-Meier analysis.
Multivariate analysis was performed using the Cox proportional hazard model. Optimum cut-offs were determined using the maximal log-rank test, and confirmed using correlation and Relationship between PAI-2 protein levels and other parameters of the PA system The median and range of values for PAI-2, uPA, PAI-1, uPAR and tPA are summarized in Table 2 . PAI-2 levels correlated weakly but significantly with both PAI-I (r = 0.175, P = 0.0315, n = 152) and uPA levels (r = 0.212, P = 0.0092, n = 152) (Figures 1 and 2) . In contrast, PAI-2 showed no significant relationship with either tPA or uPAR levels.
Detection of mRNA for PAI-2 using Northern blotting Figure 3 shows typical Northern blots for PAI-2 mRNA. Transcripts for this species were detected in 14 out of 49 (28.6%) of the primary cancers. Transcripts for uPA were found in 75.6% of samples: PAI-1, 28.6%; uPAR, 57.1%; and tPA, 30.6%. No significant correlation was found between PAI-2 mRNA levels and those for PAI-1, uPA, uPAR and tPA. In contrast to PAI-2, PAI-I mRNA levels were significantly related to those of uPA (r = 0.318, P = 0.0391, n = 43). Using the monoclonal antibody HDPAI-2 22.1, cytoplasmic and membrane staining for PAI-2 was found in both malignant and stromal cells. However, immunostaining was detected predominantly in malignant cells (Figure 4) . The staining scores for these two cell types are summarized in Table 3 Table 4 compares the prognostic value of PAI-2 with uPA, PAI-I and tPA. Using univariate analysis, the prognostic impact of PAI-2 was less strong than the other three parameters. However, in multivariate analysis, PAI-2 as a prognostic marker was independent of uPA, PAI-I and tPA. Similarly, uPA, PAI-I and tPA were independent prognostic factors. uPAR was not included in this comparative study, as results for this component were only available on 115 primary cancers. Finally, PAI-2 was investigated for possible prognostic value in different subgroups of patients with breast cancer (Table 5) . Using the optimum cut-off point, PAI-2 levels were significantly related to outcome in the following subgroups: nodepositive, ER-negative and patients with high levels of uPA (i.e. > 0.81 ng mg-' protein, which was the optimum cut-off point for discriminating between patients with good and poor outcome).
DISCUSSION
Although PAI-I has been widely studied in different human cancers, much less information is available on PAI-2. As with PAI-1 (Reilly et al, 1992) , we show here that PAI-2 protein levels are also significantly correlated with those for uPA in breast cancer. However, the relationship between PAI-2 and uPA is less strong than that between PAI-I and uPA. PAI-2 concentrations correlated weakly but significantly with those for PAI-I levels at the protein but not at the mRNA level. Similar correlations between levels of PAI-2 protein and both uPA and PAI-1 have been reported by others (Foucre et al, 1991; Foekens et al, 1995) . The lack of correlation at the mRNA level may be due to the smaller number of samples used for Northern blotting than for ELISA.
Using immunocytochemistry, we show that PAI-2 protein is found principally in malignant cells but is also present in stromal cells. Relatively little work appears to have been published on the detection of PAI-2 by immunocytochemistry in breast cancer. Using unprocessed tissue we previously found, using both monoclonal and polyclonal antibodies, that PAI-i was mostly confined to tumour cells in breast cancer (Reilly et al, 1992) . However, using paraffin-embedded tissue Bianchi et al (1995) found that PAI-i was predominantly located in stromal cells, although epithelial cell staining was also present. In colon cancer, PAI-I mRNA was found principally in endothelial cells. In this malignancy, no mRNA for PAI-I was detected in the cancer cells (Pyke et al, 1991) . Time (years) Figure 5 A Relationship between PAI-2 levels and disease free interval using an optimum cut-off point of 0.1 ng mg-' protein. Differences in outcome were determined using the log-rank test, and the optimum cut-off point was calculated using the maximal log-rank test. There were eight (40%) relapses in the low PAI-2 group compared with 35 (27.34%) in the high PAI-2 group. Chi-square = 4.25; P = 0.0392; RR = 1.91. B Relationship between PAI-2 levels and overall survival using an optimum cut-off point of 0.1 ng mg-' protein. Differences in outcome were determined using the log-rank test, and the optimum cut-off point was calculated using the maximal log-rank test. Chi-square = 6.45; P = 0.0211; RR = 2.19
Our median levels for PAI-2 protein are lower than those previously reported (Foucre et al, 1991; Sumiyoshi et al, 1992; Foekens et al, 1995) . These differences are probably related to the different assays used, i.e. different standards and different antibodies. However, our median values for PAI-2, PAI-1, uPA and uPAR are very similar to those previously reported by us (Duggan et al, 1995) . In agreement with other investigators, we found no significant relationship between PAI-2 protein levels and established prognostic markers for breast cancer such as tumour size, nodal status and ER status (Foucre et al, 1991) . Using the median value as a cut-off point, Foekens et al (1995) found no significant relationship between PAI-2 levels and either lymph node status or ER status, but did find that PAI-2 levels were significantly higher in smaller than larger tumours. In contrast to these findings, Sumiyoshi et al (1992) reported that PAI-2 levels were higher in carcinomas without than with nodal metastases. The pathophysiological significance of the presence of both PAI-I and PAI-2 in cancer is unclear. As one of the functions of these molecules is to inhibit uPA, it might be expected that high levels of these inhibitors would minimize cancer invasion and metastasis. In model systems, both PAI-I and PAI-2 have indeed been shown to do this (see Introduction). However, in human breast cancer, high levels of PAI-I are associated with poor prognosis (Gr0ndahl-Hansen et al, 1993; Janicke et al, 1993; Foekens et al, 1994) . These findings suggest that PAI-i plays a role in the spread of cancer, perhaps by protecting the tumour from proteolysis during metastasis (Reilly et al, 1992) .
Unlike PAI-1, high levels of PAI-2 do not appear to be associated with aggressive disease in breast cancer. Using an optimum cut-off point (i.e. 14.5 ng mg-' protein) Bouchet et al (1994) reported that high levels of PAI-2 were associated with both a longer disease-free interval and metastasis-free survival. In this study, however, only 14% of patients had high levels of PAI-2. In our study using an optimum cut-off of 0.1 ng mg-' protein, only 12.5% of patients had a low level of PAI-2. Foekens et al (1995) found no relationship between PAI-2 levels and patient outcome in the overall population. However, in patients with high levels of uPA, increasing PAI-2 levels were associated with improved prognosis. In this investigation we also show that PAI-2 levels correlate with outcome in patients with high uPA levels. However, we also show that PAI-2 is prognostic in other subgroups of patients generally associated with aggressive disease, i.e. node-positive and ERnegative patients. Our results with uPA, PAI-I and tPA, reported here, are in agreement with published data. Many different groups have shown that both uPA (for review see Duffy, 1996) and PAI-I (see above) are strong and independent prognostic factors in breast cancer. Using an immunoradiometric assay (IRMA), we have reported previously that high levels of tPA predicted improved outcome in patients with breast cancer (Duffy et al, 1988) . It should be pointed out, however, that the optimum cut-off point found for tPA using the present ELISA is lower than that previously obtained using IRMA. Again, the differences will probably relate to different standards and antibodies used in the ELISA and IRMA. The optimum cut-off point found for uPA in the present study was identical to that used in the previous study using the American Diagnostica ELISA (Duggan et al, 1995) .
We conclude that high PAI-2 levels, unlike those for PAI-1, are not associated with aggressive disease. On the other hand, high levels of PAI-2 may correlate with good prognosis, at least in certain subgroups of patients. These findings suggest that PAI-2 may be a favourable prognostic marker in breast cancer.
